there has been strong selling for quite some time now. All unexplained and unaccounted for so far, so we should take that as being churn from retail investors. I don't buy that though.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025